Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series
Tumori Journal · 04.06.2026
DOI: 10.1177/03008916261449595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tumori Journal, online erschienen am 04.06.2026. Verfasst von Margherita Piccinelli und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Alectinib, a second-generation ALK inhibitor, is used in first-line and adjuvant treatment for ALK- rearranged NSCLC, and has proven to be both effective and well tolerated. Gastrointestinal (GI) perforation is an extremely rare but potentially life-threatening complication, with only sporadic cases reported in the literature.
Methods
We describe, to the best of our knowledge, the largest case series to date of GI perforations that occurred during alectinib treatment in patients with ALK- rearranged NSCLC. Clinical features, management strategies, and outcomes were analyzed and integrated with available literature.
Results
Three female patients developed GI perforation after variable durations of alectinib treatment, ranging from one month to over three years. Two cases were associated with pre-existing diverticulosis, while one occurred in the absence of any known GI comorbidities. Management included conservative treatment with intravenous antibiotics in two cases and surgical intervention in one. Alectinib was permanently discontinued in all patients. Subsequent therapeutic strategies included lorlatinib or brigatinib, with heterogeneous tolerability and outcomes. Literature review identified other reports of GI perforation or severe toxicity under alectinib.
Conclusions
Although rare, GI perforation, represents a clinically relevant adverse event associated with alectinib, particularly in patients with diverticulosis or other predisposing conditions. It is essential to optimize safety and long-term disease control by raising awareness of early warning symptoms, conducting a baseline GI evaluation in high-risk patients and carefully sequencing therapy after discontinuation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
- Central Drug Production Unit, Hospital Pharmacy, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
ORCID-Profile: Margherita Piccinelli, Teresa Beninato, Laura Mazzeo, Mario Occhipinti
Zitieren
APA
Piccinelli, M., Squitieri, R., Romanò, R., Marchesi, S., Montelatici, G., Damonte, C., Brambilla, M., Beninato, T., Mazzeo, L., Corrao, G., Meazza Prina, M., Prelaj, A., Proto, C., Galassi, M., De Braud, F. G. M., Lo Russo, G., Occhipinti, M., & Ambrosini, P. (2026). Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series. Tumori Journal. https://doi.org/10.1177/03008916261449595
Vancouver
Piccinelli M, Squitieri R, Romanò R, Marchesi S, Montelatici G, Damonte C, et al. Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series. Tumori Journal. 2026. doi:10.1177/03008916261449595
BibTeX
@article{Piccinelli2026,
author = {Piccinelli, Margherita and Squitieri, Raffaele and Romanò, Rebecca and Marchesi, Silvia and Montelatici, Giulia and Damonte, Camilla and Brambilla, Marta and Beninato, Teresa and Mazzeo, Laura and Corrao, Giulia and Meazza Prina, Marco and Prelaj, Arsela and Proto, Claudia and Galassi, Margherita and De Braud, Filippo Guglielmo Maria and Lo Russo, Giuseppe and Occhipinti, Mario and Ambrosini, Paolo},
title = {Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series},
journal = {Tumori Journal},
year = {2026},
doi = {10.1177/03008916261449595}
}
EUVIMED